IBV Specific Neutra™ Antibody Products

Creative Biolabs provides a series of Influenza B Virus antibody products and services to meet the various needs of researchers. Our offerings include:

• High-affinity antibodies for specific detection of Influenza B Virus antigens.
• Custom antibody development services tailored to your unique research requirements.
• Antibody characterization and validation services to ensure data reliability.
• Assay development support for Influenza B Virus research.

Our solutions deliver the tools and expertise necessary to overcome the obstacles in Influenza B Virus research.

Contact our team to get an inquiry now!

Introduction of Influenza B Virus

Influenza B virus (IBV), Orthomyxoviridae member, persists as a clinically consequential agent of seasonal respiratory pathology, disproportionately impacting pediatric and geriatric cohorts despite lacking zoonotic reservoirs. Its eight-segment, negative-sense RNA genome encodes the canonical HA/NA glycoprotein dyad, with HA’s α2,6-linked sialic acid tropism dictating upper respiratory tract epithelial tropism—a niche fidelity distinguishing it from broader-tissue-tropic influenza A variants. IBV replication is choreographed through HA-mediated clathrin-dependent endocytosis, pH-dependent endosomal fusion, and nuclear import of viral ribonucleoprotein (vRNP) complexes.

Fig. 1 Overview of influenza B genome and proteins.¹

Notably, IBV’s evolutionary epidemiology is constrained by its limited host range, resulting in slower antigenic drift (∼2.3 substitutions/year in HA1) compared to influenza A. Current research dissects its immune evasion stratagems, including NS1-mediated blockade of RIG-I/MAVS signaling and PB1-F2-driven mitochondrial ROS amplification—mechanisms that dysregulate IFN-λ production in ciliated epithelial cells. Paradoxically, IBV’s reduced adaptive plasticity enhances vulnerability to broadly neutralizing antibodies (bnAbs) targeting HA’s conserved vestigial esterase domain, a vulnerability now being exploited in pan-IBV vaccine design.

Antibody against Influenza B Virus

Antibodies directed against influenza B virus (IBV) surface antigens—notably the hemagglutinin (HA) stalk domain and neuraminidase (NA) catalytic pocket—orchestrate both seroconversion-mediated immunity and vaccine-derived protection through dual mechanisms: steric hindrance of receptor avidity and Fc-effector recruitment. Recent breakthroughs in humoral immunology have yielded mAbs with pan-IBV efficacy, exemplified by the BDA-11 mAb targeting HA’s fusion peptide-proximal hydrophobic groove, which neutralizes all IBV lineages with picomolar potency and confers cross-protection in ferret challenge models.

Structural virology studies reveal that broadly neutralizing mAbs engage quaternary epitopes spanning HA1-HA2 interfaces or NA’s conserved enzymatic cleft, leveraging heterosubtypic breadth through glycan-shield penetration or sialic acid mimetic strategies. These mAbs synergistically activate alveolar macrophage phagocytosis via FcγRIIIa engagement while blocking HA’s pH-dependent conformational rearrangements, as evidenced by cryo-EM reconstructions of HA–Fab complexes.

Why Choose Us?

Creative Biolabs tries its best to provide you with exceptional products and services. Our Influenza B Virus antibody solutions stand out due to:

• Unparalleled Expertise: Consisting of experienced scientists, we can support you in antibody engineering, virology, and assay development.
• Advanced Technology: Utilizing cutting-edge technologies, we have high-throughput screening platforms, innovative protein engineering techniques, and state-of-the-art characterization methods.
• Specificity and Sensitivity: With high specificity and sensitivity, our antibodies are able to help your research with accurate and reliable results.
• Customization: We offer customized solutions to meet your special research needs, ranging from custom antibody development to assay optimization.
• Quality Assurance: The highest standards of our product quality and consistency are ensured by our strict quality control processes.

FAQs

For more information about Creative Biolabs' Influenza B Virus antibodies and services, please contact us.

REFERENCE

1. Ashraf, Muhammad Awais, et al. "A comprehensive review of influenza B virus, its biological and clinical aspects." Frontiers in microbiology 15 (2024): 1467029. Distributed under Open Access license CC BY 4.0, without modification.